AOBO announces commercial launch of osteoporosis drug Yi Shen Jian Gu Gel

American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced the commercial launch of Boke brand Yi Shen Jian Gu Gel ("YSJG" Gel) after successful test marketing in the second quarter of 2010.

Boke YSJG Gel aims at alleviating osteoporosis. A report issued by China's Ministry of Health ("MOH") shows that between 35 and 40 million people in China, or about 3% of the population, have osteoporosis, and the number of patients is expected to increase to 150 million by the year 2025.

The main active ingredient of YSJG Gel is Rhizoma Homalomenae, as well as ginseng, safflower, and fleece flower root, and is granted proprietary status by China's SFDA.

Mr. Tony Liu, Chairman and CEO of AOBO, commented, "The addressable market is large and growing for this product. We intend to make use of YSJG's proprietary drug status and Boke's brand image in our marketing."

SOURCE American Oriental Bioengineering, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Heavier birth weight is linked to higher risk of bone fracture later in life